Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Oncology Briefings™: How Do the Experts Approach Newly Diagnosed Multiple Myeloma?
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care
View More
Community Practice Connections™: The 2nd Annual Hawaii Lung Cancers Conference®
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Educating Patients and Providers: Key Takeaways for Better VMS Management
March 28th 2025Panelists discuss how providers should actively screen for vasomotor symptoms (VMS), especially given the lengthy wait times to see specialists, emphasizing that education for both patients and health care providers is essential for timely intervention and effective management.
Liver Safety and Monitoring in VMS Treatment
March 28th 2025Panelists discuss how fezolinetant and elinzanetant can cause liver-related adverse events requiring careful monitoring for drug-induced liver injury, noting that patients typically recover after discontinuation and emphasizing that primary providers are ideally positioned to manage patients with complex comorbidities.
Beyond Hormone Therapy: Effective Alternatives for Managing Menopausal Symptoms
March 28th 2025Panelists discuss how previous therapies lacked efficacy for vasomotor symptoms, while new treatments fezolinetant and elinzanetant offer superior effectiveness, with elinzanetant specifically addressing additional symptoms beyond the primary condition.
Understanding VMS in Menopause: Prevalence and Impact
March 28th 2025Panelists discuss how vasomotor symptoms (VMS) can persist for years with variable manifestations, significantly disrupting both social and professional spheres, resulting in multibillion-dollar economic losses through decreased productivity and increased insurance costs.